Covid-19 Antibody Maker HyTest Said to Mull $400 Million Sale
- Nordic buyout firm Summa Equity acquired HyTest in 2018
- Finnish company expects antibodies to detect virus variants
Photographer: Stepfanie Loos/AFP/Getty Images
This article is for subscribers only.
Nordic private equity firm Summa Equity AB is exploring a sale of Finland’s HyTest Ltd., a manufacturer of antibodies and antigens used in tests for illnesses including Covid-19, people with knowledge of the matter said.
Summa is working with advisers on the potential divestment and has reached out to prospective suitors, said the people, who asked not to be identified as the information is private. HyTest could fetch as much as $400 million in a sale, the people said, citing strong investor interest in testing due to the pandemic.